For an 87‑year‑old patient whose susceptibility testing shows amoxicillin/clavulanic acid susceptible, ampicillin resistant, cefazolin resistant, cefepime susceptible, cefoxitin susceptible, cefpodoxime intermediate, ceftriaxone resistant, ciprofloxacin resistant, ertapenem susceptible, gentamicin susceptible, levofloxacin resistant, meropenem susceptible, nitrofurantoin susceptible, piperacillin/tazobactam susceptible, tetracycline susceptible, tobramycin susceptible, and trimethoprim/sulfamethoxazole resistant, which antibiotic regimen should be initiated?

Antibiotic Selection for 87-Year-Old Patient

Based on the susceptibility profile showing resistance to fluoroquinolones, ceftriaxone, and trimethoprim-sulfamethoxazole, I recommend initiating treatment with either amoxicillin/clavulanic acid, nitrofurantoin, or piperacillin/tazobactam, depending on the infection source and severity.

Clinical Context Assessment

The susceptibility pattern reveals an ESBL-producing organism (likely E. coli), evidenced by:

• Ampicillin resistance with amoxicillin/clavulanic acid susceptibility
• Cefazolin and ceftriaxone resistance with cefepime susceptibility
• Fluoroquinolone resistance (ciprofloxacin, levofloxacin)

This is a critical finding in an 87-year-old patient, as ESBL infections require careful antibiotic selection to avoid treatment failure and preserve carbapenem options.

Recommended Treatment Algorithm

For Uncomplicated Urinary Tract Infection:

First-line options:

• Nitrofurantoin (if GFR >30 mL/min and no upper tract involvement) 1
• Amoxicillin/clavulanic acid 875/125 mg twice daily 2

Rationale: Both agents show susceptibility and are appropriate for lower UTI in elderly patients. Nitrofurantoin achieves excellent urinary concentrations and has minimal impact on gut microbiome 3.

For Pyelonephritis or Complicated UTI:

Step-down oral therapy:

• Amoxicillin/clavulanic acid 875/125 mg three times daily for 10-14 days 2

Initial IV therapy (if hospitalized):

• Ertapenem 1 g IV daily 4, 2
• Meropenem 1 g IV every 8 hours 4, 5
• Piperacillin/tazobactam 3.375-4.5 g IV every 6-8 hours 4, 2

For Intra-Abdominal Infection:

Preferred regimen:

• Ertapenem 1 g IV every 24 hours 4, 2
• Meropenem 1 g IV every 8 hours 4, 5

Alternative:

• Piperacillin/tazobactam 3.375 g every 6 hours 4, 2

Critical Considerations for This Patient

Age-Related Factors (87 years old):

1. Renal function assessment is mandatory - Adjust all dosing based on creatinine clearance 5
2. Avoid aminoglycosides (gentamicin, tobramycin) despite susceptibility due to nephrotoxicity and ototoxicity risk in elderly 2
3. Nitrofurantoin contraindicated if GFR <30 mL/min 1

Antimicrobial Stewardship Priorities:

Reserve carbapenems when possible: The 2023 ESCMID guidelines emphasize limiting carbapenem use if alternatives are available 2. However, for severe ESBL infections, carbapenems remain the preferred regimen, with ertapenem preferred over meropenem/imipenem for non-severe infections due to single daily dosing and to preserve broader-spectrum carbapenems 2.

Avoid These Options:

• Fluoroquinolones (ciprofloxacin, levofloxacin) - Resistant 6
• Ceftriaxone - Resistant 4
• Trimethoprim/sulfamethoxazole - Resistant 7
• Cefazolin - Resistant (ESBL pattern) 4

Specific Dosing Adjustments

If Renal Impairment Present:

Ertapenem: Reduce to 500 mg daily if CrCl <30 mL/min 5

Meropenem:

• CrCl 26-50 mL/min: 1 g every 12 hours
• CrCl 10-25 mL/min: 500 mg every 12 hours 5

Piperacillin/tazobactam: Reduce frequency based on CrCl 4

Duration of Therapy

• Uncomplicated cystitis: 5-7 days 3
• Pyelonephritis: 10-14 days 2
• Complicated intra-abdominal infection: 4-7 days after source control 4
• Bacteremia: 10-14 days minimum 8

Common Pitfalls to Avoid

1. Do not use cefpodoxime - Shows intermediate susceptibility, inadequate for serious infection 9
2. Do not rely on tetracycline despite susceptibility - inadequate for systemic infections 10
3. Verify infection source - Treatment differs significantly between UTI, intra-abdominal, and skin/soft tissue infections 4, 11, 12
4. Monitor for Clostridioides difficile - High-risk patient (age >65, antibiotic exposure) 11